October 26, 2020
Podcast
A glimpse into FDA advisor perspective just weeks before EUAs are anticipated to be sent.
Article
The company is planning to move forward after receiving a recommendation from the DSMB to start up the trial again.
October 23, 2020
The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.
Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.
October 21, 2020
The participant was taking a placebo and the trial will continue according to initial reports.
A vaccine developer joins for a firsthand discussion on the development, research, and distribution process.
October 17, 2020
Many unknowns remain as the scientific community focuses on its goal of issuing a vaccine for COVID-19.
October 16, 2020
Video
Covaxx has developed its investigational vaccine and is currently in a phase 1/2 trial.
Pfizer anticipates to have completed FDA-mandated safety data a month from now. An EUA application should shortly follow.
October 15, 2020
Data from a Phase 1/2 randomized controlled trial of vaccine candidate, BBIBP-CorV, is shown to be safe.
